EIF3J

Across TCGA pan-cancer cohorts, EIF3J mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF3J data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF3J mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EIF3J expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where EIF3J mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.540	0.951	.017	15	view →
GBM	OS	Tertile	All	0.605	0.874	.004	12	view →
LUAD	DFS	Quartile	II,III,IV	0.174	0.672	.007	9	view →
LSCC	DFS	Tertile	All	0.959	0.877	.047	3	view →
CCRCC	OS	Quartile	All	0.660	1.000	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF3J–PDAC (OS)

Open the PDAC breakdown →